Literature DB >> 25941599

Chimeric antigen receptor T cells are vulnerable to immunosuppressive mechanisms present within the tumor microenvironment.

Gregory L Beatty1, Edmund K Moon2.   

Abstract

Chimeric antigen receptor (CAR) modified T cells have shown early promise in hematological malignancies. However, in solid malignancies CAR T cells must overcome a distinct immunosuppressive microenvironment which may compromise their capacity to mediate antitumor activity.

Entities:  

Keywords:  CAR, chimeric antigen receptor; Lag3, lymphocyte-activation gene 3; PD1, programmed cell death 1; PDL1, programmed death ligand 1; TIM3, T cell immunoglobulin domain and mucin domain 3; adoptive cell therapy; cancer; chimeric antigen receptor T cells; immune checkpoint molecules; tumor microenvironment

Year:  2014        PMID： 25941599      PMCID： PMC4292547          DOI： 10.4161/21624011.2014.970027

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  6 in total

1.  Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor.

Authors:  Yangbing Zhao; Edmund Moon; Carmine Carpenito; Chrystal M Paulos; Xiaojun Liu; Andrea L Brennan; Anne Chew; Richard G Carroll; John Scholler; Bruce L Levine; Steven M Albelda; Carl H June
Journal:  Cancer Res       Date:  2010-10-05       Impact factor: 12.701

2.  Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies.

Authors:  Gregory L Beatty; Andrew R Haas; Marcela V Maus; Drew A Torigian; Michael C Soulen; Gabriela Plesa; Anne Chew; Yangbing Zhao; Bruce L Levine; Steven M Albelda; Michael Kalos; Carl H June
Journal:  Cancer Immunol Res       Date:  2014-02       Impact factor: 11.151

3.  Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains.

Authors:  Carmine Carpenito; Michael C Milone; Raffit Hassan; Jacqueline C Simonet; Mehdi Lakhal; Megan M Suhoski; Angel Varela-Rohena; Kathleen M Haines; Daniel F Heitjan; Steven M Albelda; Richard G Carroll; James L Riley; Ira Pastan; Carl H June
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-11       Impact factor: 11.205

Review 4.  The basic principles of chimeric antigen receptor design.

Authors:  Michel Sadelain; Renier Brentjens; Isabelle Rivière
Journal:  Cancer Discov       Date:  2013-04-02       Impact factor: 39.397

5.  Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors.

Authors:  Edmund K Moon; Liang-Chuan Wang; Douglas V Dolfi; Caleph B Wilson; Raghuveer Ranganathan; Jing Sun; Veena Kapoor; John Scholler; Ellen Puré; Michael C Milone; Carl H June; James L Riley; E John Wherry; Steven M Albelda
Journal:  Clin Cancer Res       Date:  2014-06-11       Impact factor: 12.531

Review 6.  Discovery of mesothelin and exploiting it as a target for immunotherapy.

Authors:  Ira Pastan; Raffit Hassan
Journal:  Cancer Res       Date:  2014-05-13       Impact factor: 12.701
  6 in total
  28 in total

Review 1.  The basics of CAR T design and challenges in immunotherapy of solid tumors - Ovarian cancer as a model.

Authors:  Xuequn Xu; Jin Qiu; Yi Sun
Journal:  Hum Vaccin Immunother       Date:  2017-03-08       Impact factor: 3.452

Review 2.  Co-stimulatory and co-inhibitory pathways in cancer immunotherapy.

Authors:  Rachel E O'Neill; Xuefang Cao
Journal:  Adv Cancer Res       Date:  2019-04-17       Impact factor: 6.242

3.  PD1 Blockade Enhances ICAM1-Directed CAR T Therapeutic Efficacy in Advanced Thyroid Cancer.

Authors:  Katherine D Gray; Jaclyn E McCloskey; Yogindra Vedvyas; Olivia R Kalloo; Steve El Eshaky; Yanping Yang; Enda Shevlin; Marjan Zaman; Timothy M Ullmann; Heng Liang; Dessislava Stefanova; Paul J Christos; Theresa Scognamiglio; Andrew B Tassler; Rasa Zarnegar; Thomas J Fahey; Moonsoo M Jin; Irene M Min
Journal:  Clin Cancer Res       Date:  2020-09-04       Impact factor: 12.531

Review 4.  Engineered T cells: the promise and challenges of cancer immunotherapy.

Authors:  Andrew D Fesnak; Carl H June; Bruce L Levine
Journal:  Nat Rev Cancer       Date:  2016-08-23       Impact factor: 60.716

Review 5.  Understanding and Managing Large B Cell Lymphoma Relapses after Chimeric Antigen Receptor T Cell Therapy.

Authors:  Michael Byrne; Olalekan O Oluwole; Bipin Savani; Navneet S Majhail; Brian T Hill; Fredrick L Locke
Journal:  Biol Blood Marrow Transplant       Date:  2019-07-04       Impact factor: 5.742

Review 6.  The current landscape of immunotherapy for pediatric brain tumors.

Authors:  Eugene I Hwang; Elias J Sayour; Catherine T Flores; Gerald Grant; Robert Wechsler-Reya; Lan B Hoang-Minh; Mark W Kieran; Joanne Salcido; Robert M Prins; John W Figg; Michael Platten; Kate M Candelario; Paul G Hale; Jason E Blatt; Lance S Governale; Hideho Okada; Duane A Mitchell; Ian F Pollack
Journal:  Nat Cancer       Date:  2022-01-20

Review 7.  Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy.

Authors:  Mark O'Hara; Caitlin Stashwick; Andrew R Haas; Janos L Tanyi
Journal:  Immunotherapy       Date:  2016       Impact factor: 4.196

Review 8.  Broadening the Impact of Immunotherapy to Pancreatic Cancer: Challenges and Opportunities.

Authors:  Vinod P Balachandran; Gregory L Beatty; Stephanie K Dougan
Journal:  Gastroenterology       Date:  2019-01-18       Impact factor: 22.682

Review 9.  Beyond immune checkpoint blockade: emerging immunological strategies.

Authors:  Shawn P Kubli; Thorsten Berger; Daniel V Araujo; Lillian L Siu; Tak W Mak
Journal:  Nat Rev Drug Discov       Date:  2021-03-08       Impact factor: 84.694

10.  Adenosine Deaminase 1 Overexpression Enhances the Antitumor Efficacy of Chimeric Antigen Receptor-Engineered T Cells.

Authors:  Yun Qu; Zachary S Dunn; Xianhui Chen; Melanie MacMullan; Gunce Cinay; Hsuan-Yao Wang; Jiangyue Liu; Fangheng Hu; Pin Wang
Journal:  Hum Gene Ther       Date:  2021-08-25       Impact factor: 4.793
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.